Realcan Pharmaceutical Group (002589.SZ) announced on June 14th that, based on its business expansion and deepening market strategy, the company plans to jointly invest with Meyite Biomedical (Wuhan) Co., Ltd. (referred to as "Meyite") to establish a joint venture to build a human intestinal microbiota function mining and clinical application technology development base. The company will authorize the intestinal flora transplantation medical technology it holds and/or its affiliates to conduct exclusive cooperation in the agreed cooperation area and channel range, including but not limited to distribution, sales, promotion, etc., to promote the deep integration of probiotic research and development technology in the medical institution service field. The total investment of the joint venture is expected to be RMB 10 million.
瑞康医药(002589.SZ)：拟与美益添设立合资公司 共建人体肠道微生物功能挖掘及临床应用技术开发基地
Realcan Pharmaceutical Group (002589.SZ) plans to establish a joint venture with Mayiti to jointly build a human intestinal microbiota function excavation and clinical application technology development base.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.